- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT03742102
Uno studio su nuovi agenti antitumorali in pazienti con carcinoma mammario triplo negativo metastatico (BEGONIA)
Uno studio di fase IB/II, in 2 fasi, in aperto, multicentrico per determinare l'efficacia e la sicurezza di Durvalumab (MEDI4736) + Paclitaxel e Durvalumab (MEDI4736) in combinazione con nuove terapie oncologiche con o senza paclitaxel per la tripla metastatica di prima linea Cancro al seno negativo
This study is designed to determine the efficacy and safety of durvalumab in combination with novel oncology therapies with or without paclitaxel and durvalumab + paclitaxel for first-line metastatic triple negative breast cancer
Panoramica dello studio
Stato
Condizioni
Descrizione dettagliata
This is a Phase IB/II, 2-stage, open-label, multicenter study to determine the efficacy and safety of durvalumab in combination with novel oncology therapies (i.e. therapies designed for immune modulation) with or without paclitaxel and durvalumab + paclitaxel as first-line treatment in patients with metastatic triple negative breast cancer (TNBC). The study is designed to concurrently evaluate potential novel treatment combinations with clinical promise using a 2-stage approach. The study will use a Simon 2-Stage design to evaluate which cohorts may proceed to expansion.
Part 1 is a Phase IB study of safety and initial efficacy, and Part 2 may expand patient enrollment if adequate efficacy signal is observed in Part 1. The treatment regimens evaluated in Part 2 will depend on the evaluation of safety and efficacy outcomes in Part 1.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
- Fase 1
Contatti e Sedi
Luoghi di studio
-
-
British Columbia
-
Kelowna, British Columbia, Canada, V1Y 5L3
- Research Site
-
-
Ontario
-
London, Ontario, Canada, N6A 4L6
- Research Site
-
-
Quebec
-
Greenfield Park, Quebec, Canada, J4V 2H1
- Research Site
-
Montreal, Quebec, Canada, H4A 3J1
- Research Site
-
-
-
-
-
Seoul, Corea del Sud, 03080
- Research Site
-
Seoul, Corea del Sud, 05505
- Research Site
-
Seoul, Corea del Sud, 06351
- Research Site
-
-
-
-
-
Gdansk, Polonia, 80-952
- Research Site
-
Krakow, Polonia, 31-501
- Research Site
-
Lublin, Polonia, 20-090
- Research Site
-
Opole, Polonia, 45-060
- Research Site
-
Rzeszów, Polonia, 35-021
- Research Site
-
Warsaw, Polonia, 02-781
- Research Site
-
Warsaw, Polonia, 04-141
- Research Site
-
-
-
-
-
Cambridge, Regno Unito, CB2 0QQ
- Research Site
-
London, Regno Unito, EC1M 6BQ
- Research Site
-
Manchester, Regno Unito, M20 4BX
- Research Site
-
Oxford, Regno Unito, OX3 7LE
- Research Site
-
-
-
-
Arizona
-
Tucson, Arizona, Stati Uniti, 85715
- Research Site
-
-
Maryland
-
Columbia, Maryland, Stati Uniti, 21044
- Research Site
-
-
Massachusetts
-
Boston, Massachusetts, Stati Uniti, 02114
- Research Site
-
Boston, Massachusetts, Stati Uniti, 02215
- Research Site
-
-
Michigan
-
Grand Rapids, Michigan, Stati Uniti, 49503
- Research Site
-
-
Missouri
-
St Louis, Missouri, Stati Uniti, 63110
- Research Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75246
- Research Site
-
-
Virginia
-
Williamsburg, Virginia, Stati Uniti, 23188
- Research Site
-
-
-
-
-
Kaohsiung City, Taiwan, 80756
- Research Site
-
Taichung, Taiwan, 40447
- Research Site
-
Tainan, Taiwan, 70403
- Research Site
-
Taipei, Taiwan, 10002
- Research Site
-
Taipei, Taiwan, 112
- Research Site
-
Taoyuan, Taiwan, 333
- Research Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion criteria
- Female
- At least 18 years of age at the time of screening
- Patient must have locally confirmed advanced/unresectable or metastatic TNBC.
- No prior treatment for metastatic (Stage IV) TNBC
- Patient must have at least 1 lesion, not previously irradiated, that can be accurately measured
- WHO/ECOG status at 0 or 1 at enrollment
Patients enrolled to Arm 6 (durvalumab and DS-8201a) Must provide documentation of locally determined advanced/unresectable or metastatic TNBC with HER2 low tumor expression (IHC 2+/ISH-, IHC 1+/ISH-, or IHC 1+/ISH untested)
Patients enrolled in Arm 8 (durvalumab + Dato-DXd) Must have PD-L1 positive tumor as determined by an IHC based assay
Exclusion criteria
- History of allogeneic organ transplantation
- Active or prior documented autoimmune or inflammatory disorders
- Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg] result), hepatitis C virus (HCV), or human immunodeficiency virus (positive HIV 1/2 antibodies)
- Untreated CNS metastases
- Known allergy or hypersensitivity to any of the study drugs or any of the study drug excipients
- Any concurrent chemotherapy, IP, or biologic therapy for cancer treatment
- Female patients who are pregnant, breastfeeding
- Cardiac Ejection Fraction less than 50%
Patients enrolled in Arm 2 only:
- Potent inhibitors or inducers or substrates of CYP3A4 or substrates of CYP2C9 or CYP2D6 within 2 weeks before the first dose of study treatment (3 weeks for St John's Wort)
- Diagnosis of diabetes mellitus Type I or diabetes mellitus Type II requiring insulin treatment.
- Any factors that increase the risk of QTc prolongation or risk of arrhythmic events, such as heart failure, hypokalemia, potential for torsades de pointes, congenital long QT syndrome, family history of long QT syndrome or unexplained sudden death under 40 years of age, or any concomitant medication known to prolong the QT interval
- Prior treatment with PI3K inhibitors, AKT inhibitors, or mammalian target of rapamycin (mTOR) inhibitors.
Patients enrolled in Arm 5 only: History of venous thromboembolism in the past 3 months
Patients enrolled in Arm 7 and 8 only: Clinically significant corneal disease in the opinion of the Investigator.
Patients enrolled in Arm 6, 7 and 8 only:
- History of or active interstitial lung disease/pneumonitis
- Use of chloroquine or hydroxychloroquine in <14 days prior to Day 1 of DS-8201a (Arm 6) or Dato-DXd (DS-1062a; Arm 7 and 8) treatment
- Patients enrolled in Arm 6 only: Previously been diagnosed as HER2+ or received HER2-targeted therapy.
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Arm 1
durvalumab + paclitaxel |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off |
|
Sperimentale: Arm 2
durvalumab + paclitaxel + capivasertib |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off Capivasertib oral bid 4-week cycles; 3 weeks on (dosing on days 2,3,4 and 5) and 1 week off
Altri nomi:
|
|
Sperimentale: Arm 5
durvalumab + paclitaxel + oleclumab |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Paclitaxel iv 4-week cycles: 3 weeks once weekly (q1w) and 1 week off Oleclumab iv Every 2 weeks (q2w) for first 2 cycles (days 1 and 15 in cycles 1 and 2), then every 4 weeks (q4w) starting at cycle 3 day 1
Altri nomi:
|
|
Sperimentale: Arm 6
durvalumab + trastuzumab deruxtecan |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Trastuzumab deruxtecan iv 3-week cycles (once weekly) q3w
Altri nomi:
|
|
Sperimentale: Arm 7
durvalumab + datopotamab deruxtecan |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Altri nomi:
|
|
Sperimentale: Arm 8
durvalumab + datopotomab deruxtecan (patients with PD-L1 positive status) |
Durvalumab iv Every 4 weeks (q4w) or 3 weeks (q3w) Arm 6, 7 and 8
Altri nomi:
Datopotamab deruxtecan iv 3-week cycles (once weekly) q3w
Altri nomi:
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Dose Limiting Toxicity (DLT) Events
Lasso di tempo: From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
|
The occurrence of a severe adverse event (meeting pre-specified criteria) that is at least possibly related to durvalumab and/or the novel oncology therapy in 6 DLT-evaluable patients |
From the time of first dose until completion of the first cycle (28 days for Arms 2-5, 21 days for Arms 6-7 (no safety run-in for Arms 1 and 8))
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Objective Response Rate (ORR)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Percentage of evaluable patients with a confirmed Investigator-assessed response of CR (complete response) or PR (partial response). Confirmed response is defined as at least one visit response of CR or PR confirmed by a follow-up scan at least 4 weeks later showing CR or PR. |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Progression-free Survival (PFS)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of objective radiological disease progression using RECIST 1.1 or death (by any cause in the absence of progression) |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Duration of Response (DoR)
Lasso di tempo: Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
Time from the date of first documented response (which is subsequently confirmed) until the first date of documented progression (PD) or death in the absence of PD (ie, date of PFS event or censoring - date of first response + 1). If a patient does not progress following a response, then their DoR will be censored at the last evaluable disease assessment date |
Tumor assessments: every 8 wks (Arms 1-5) or every 6 wks (Arms 6-8) until wk 48, then every 12 wks from first IP dose until radiologic progression, death, withdrawal of consent, or study completion; up to max 54 mos (observed longest duration in Arm 1)
|
|
Overall Survival (Count)
Lasso di tempo: From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
Number of patients with overall survival, the time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause |
From date of first dose until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
|
Overall Survival (Duration)
Lasso di tempo: From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
Time from date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) until the date of death by any cause |
From date of first dose of IP until date of death due to any cause; up to the maximum of 54 months (observed longest duration in Arm 1)
|
|
Progression-free Survival at 6 Months (PFS6)
Lasso di tempo: 6 months following date of first dose
|
Percentage of patients alive and progression-free at 6 months following date of first dose (at least one study intervention [durvalumab, paclitxel or novel oncology therapy]) |
6 months following date of first dose
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Peter Schmid, MD, PhD, Barts Cancer Institute
Pubblicazioni e link utili
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Effettivo)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
- Neoplasie per sede
- Neoplasie
- Malattie della pelle
- Malattie del seno
- Malattie della pelle e del tessuto connettivo
- Neoplasie mammarie
- Neoplasie mammarie triplo negativo
- Prodotti chimici organici
- Idrocarburi
- Cicloparaffins
- Idrocarburi, aliciclici
- Idrocarburi, ciclici
- Terpeni
- Taxoidi
- Ciclodecani
- Diterpenes
- Paclitaxel
- Capivasertib
- Durvalumab
- trastuzumab deruxtecan
Altri numeri di identificazione dello studio
- D933LC00001
- 2018 (Sovvenzione/contratto NIH degli Stati Uniti)
- 2018-000764-29 (Numero EudraCT)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Periodo di condivisione IPD
AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Criteri di accesso alla condivisione IPD
When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.
Tipo di informazioni di supporto alla condivisione IPD
- STUDIO_PROTOCOLLO
- LINFA
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .